MARC Record from Library of Congress

LEADER: 03164cam a22005417a 4500
001 2010929846
003 DLC
005 20120716103459.0
008 100602s2010 nyua b 001 0 eng
010 $a 2010929846
016 7 $a101578308$2DNLM
016 7 $a015641651$2Uk
020 $a9781607618027 (alk. paper)
020 $a1607618028 (alk. paper)
020 $a9781607618034 (e-ISBN)
020 $a1607618036 (e-ISBN)
035 $a(OCoLC)ocn646113643
040 $aNLM$beng$cNLM$dBTCTA$dYDXCP$dSCB$dCUS$dMIA$dUKMGB$dDLC
042 $anlmcopyc$alccopycat
060 00 $aW1$bME9616J v.663 2010
060 10 $aQZ 170
050 00 $aRM340$b.A566 2010
082 00 $a615.7/18$223
245 00 $aAnticoagulants, antiplatelets, and thrombolytics /$cedited by Shaker A. Mousa.
250 $a2nd ed.
260 $aNew York, NY :$bHumana,$cc2010.
300 $axi, 316 p. :$bill. ;$c27 cm.
490 1 $aSpringer protocols
490 1 $aMethods in molecular biology,$x1064-3745 ;$v663
504 $aIncludes bibliographical references and index.
505 0 $aIn vitro methods of evaluating antithrombotics and thrombolytics / S.A. Mousa -- In vivo models for the evaluation of antithrombotics and thrombolytics / S.A. Mousa -- Heparin and low-molecular weight heparins in thrombosis and beyond / S.A. Mousa -- Laboratory methods and management of patients with heparin-induced thrombocytopenia / M. Prechel, W.P. Jeske and J.M. Walenga -- Novel anticoagulant therapy: Principle and practice / S.A. Mousa -- Oral direct factor xa inhibitors, with special emphasis on rivaroxaban / S.A. Mousa -- Antiplatelet therapies: Drug interactions in the management of vascular disorders / S.A. Mousa -- Prasugrel: A novel platelet adp p2y(12) receptor antagonist / S.A. Mousa, W.P. Jeske and J. Fareed -- Antithrombotic effects of naturally derived products on coagulation and platelet function / S.A. Mousa -- Assessment of anti-metastatic effects of anticoagulant and antiplatelet agents using animal models of experimental lung metastasis / A. Amirkhosravi ... [et al.] -- Adhesion molecules: Potential therapeutic and diagnostic implications / S.A. Mousa -- Pharmacogenomics in thrombosis / S.A. Mousa -- Diagnosis and management of sickle cell disorders / S.A. Mousa and M.H. Qari.
650 0 $aAnticoagulants (Medicine)
650 0 $aBlood platelets.
650 0 $aThrombolytic therapy.
650 0 $aFibrinolytic agents.
650 0 $aThrombolytic therapy$xMethods.
650 0 $aFibrinolytic agents$xTherapeutic use.
650 0 $aHeparin$xTherapeutic use.
650 12 $aAnticoagulants$xtherapeutic use.
650 12 $aThrombolytic Therapy$xmethods.
650 22 $aFibrinolytic Agents$xtherapeutic use.
650 22 $aHeparin$xtherapeutic use.
650 22 $aPlatelet Aggregation Inhibitors$xtherapeutic use.
650 22 $aThrombocytopenia$xdrug therapy.
700 1 $aMousa, Shaker A.
776 08 $iOnline version:$tAnticoagulants, antiplatelets, and thrombolytics.$b2nd ed.$dNew York, NY : Humana, c2010$w(OCoLC)743173817
830 0 $aSpringer protocols.
830 0 $aMethods in molecular biology (Clifton, N.J.) ;$vv. 663.$x1064-3745